EU/3/15/1589

About

On 15 January 2016, orphan designation (EU/3/15/1589) was granted by the European Commission to AMMTeK, France, for glibenclamide for the treatment of neonatal diabetes.

The sponsorship was transferred to Pharma Services, France, in September 2016 and back to AMMTeK, France, in February 2017.

Glibenclamide has been authorised in the EU as Amglidia since 24 May 2018.

Key facts

Active substance
Glibenclamide for the treatment of neonatal diabetes
Disease / condition
Treatment of neonatal diabetes
Date of decision
15/01/2016
Outcome
Positive
Orphan decision number
EU/3/15/1589

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Amglidia at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the PDF iconorphan medicine assessment report .

Sponsor's contact details

AMMTeK
15 rue Béranger
75003 Paris
France
Tel. +33 158 281 680
Fax +33 1 58 28 16 90
E-mail: contact@ammtek.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating